Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with adv | AcademicGPT, tlooto

Atezolizumab-bevacizumAB is the new standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC), but the optimal sequence of therapy after disease prognosis is still unclear. (2021), JOURNAL OF CLINICAL ONCOLOGY, Yoo C. | AcademicGPT, tlooto for Academic and Research